Welcome to our dedicated page for Adagene SEC filings (Ticker: ADAG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Adagene Inc. (Nasdaq: ADAG) files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, and this page aggregates those SEC filings for detailed review. The company submits Form 6-K current reports that incorporate press releases, financial statements, and transaction disclosures by reference into its registration statements on Form F-3 and Form S-8. These filings provide insight into Adagene’s clinical-stage operations, financing arrangements, collaborations, and risk disclosures related to its antibody-based cancer immunotherapy programs.
Within Adagene’s filings, investors can find information on its Dynamic Precision Library (DPL) platform, composed of NEObody, SAFEbody, and POWERbody technologies, and on its lead clinical program ADG126 (muzastotug), a masked, anti-CTLA-4 SAFEbody in development for metastatic microsatellite-stable colorectal cancer in combination with anti-PD-1 therapy. Form 6-K reports have included financial results for specified periods, descriptions of research and development and administrative expenses, and commentary on how the company prioritizes development of ADG126. They also describe strategic transactions such as Sanofi’s agreement to make a strategic investment through Series A non-voting convertible preferred shares and the associated terms of conversion, voting, dividends, and liquidation preferences.
Adagene’s SEC submissions further document collaboration and license agreements with partners including Exelixis, Sanofi, and other counterparties, as well as borrowings from various banks and related-party transactions. These disclosures outline milestone and royalty structures, option exercises for SAFEbody discovery programs, and the use of proceeds from financing activities to support clinical development of muzastotug and other research programs.
On Stock Titan, users can access Adagene’s SEC filings as they are furnished to EDGAR and use AI-powered tools to summarize complex documents. These tools can help explain key elements of Form 6-K reports, highlight material terms in agreements, and surface information on clinical development plans, capital structure, and risk factors, allowing readers to navigate lengthy regulatory filings more efficiently.
Adagene Inc. shareholder Vincent C. Smith and related entities filed an amended Schedule 13G reporting significant ownership of the company’s Ordinary Shares. Mr. Smith may be deemed to beneficially own 5,095,351 Ordinary Shares, or 8.7% of the class, including shares held directly and through affiliated entities.
The Vincent C. Smith, Jr. 2025 Annuity Trust beneficially owns 3,608,019 Ordinary Shares, representing 6.1% of the class, while VCS Master Holdings GP holds 185,701 Ordinary Shares, or 1.0%. These percentages are based on 58,914,087 Ordinary Shares outstanding as of June 30, 2025. The filing states the securities were not acquired to change or influence control of Adagene.
Adagene Inc. filed a 6-K highlighting its cash position and development plans for 2026. The company reported unaudited cash and cash equivalents of $74.5 million as of December 31, 2025, which it anticipates will fund operations until late 2027. This figure is preliminary, unaudited, subject to finalization, and is not a substitute for audited US GAAP financial statements.
Adagene’s lead program, muzastotug (ADG126), is a masked anti-CTLA-4 antibody (SAFEbody) with FDA Fast Track designation, being studied in Phase 1b/2 and Phase 2 trials in combination with anti-PD-1 therapy, particularly in microsatellite stable metastatic colorectal cancer. A data update from the ongoing Phase 1b/2 study of muzastotug plus pembrolizumab in third-line and later MSS colorectal cancer patients remains on track for Q1 2026. The company emphasizes its platform technologies (SAFEbody, NEObody, POWERbody) aimed at improving the safety and precision of antibody-based cancer immunotherapies.
Adagene Inc. filed a Form F-3 resale registration covering up to 10,625,000 ordinary shares or 8,500,000 ADSs to be offered from time to time by a selling shareholder. The registered securities are issuable upon conversion of 1,062,500 Series A Non-Voting Redeemable Convertible Preferred Shares that were sold in a private placement.
Adagene is not selling any securities and will receive no proceeds from sales under this prospectus; the selling shareholder will receive all sale proceeds. Each ADS represents 1.25 ordinary shares, and the ADSs trade on Nasdaq as ADAG. Sales may occur in public or private transactions at market or negotiated prices.
The prospectus highlights PRC-related regulatory and operational risks, including potential impacts from cybersecurity and data rules, and notes the historical HFCAA context regarding PCAOB inspections. Counsel indicates this secondary offering is not subject to CSRC filing based on current guidance.
Adagene Inc. has furnished a Form 6-K as a foreign private issuer to provide its financial results for the six-month period ended June 30, 2025. The submission points readers to two key exhibits: a press release discussing the six-month 2025 financial results and corporate update, and unaudited interim condensed consolidated financial statements for the six months ended June 30, 2024 and 2025.
The company also states that this Form 6-K, including Exhibits 99.1 and 99.2, is incorporated by reference into its existing registration statements on Form F-3 and Form S-8, so these updated results and disclosures are now legally part of those offering documents unless later superseded.
FAQ
What is the current stock price of Adagene (ADAG)?
What is the market cap of Adagene (ADAG)?
